In the last 12 months, insiders at Voyager Therapeutics, Inc. ($VYGR) filed 152 transactions with the SEC: 1 open-market purchases totaling $39,032,821 and 67 sales totaling $15,811,769. Net insider sentiment: net buying.
Voyager Therapeutics, Inc. operates in the Biological products, (no disgnostic substances) industry (Life sciences sector).
Most Active Insiders
- NEUROCRINE BIOSCIENCES INC (TenPercentOwner) — 1 transaction totaling $39,032,821
- EcoR1 Capital, LLC (TenPercentOwner) — 3 transactions totaling $7,142,343
- Third Rock Ventures III, L.P. (TenPercentOwner) — 9 transactions totaling $6,839,743
- Sandrock Alfred (President and CEO) — 17 transactions totaling $546,310
- Carter Todd Alfred (Chief Scientific Officer) — 31 transactions totaling $398,392
View all SEC Filings for Voyager Therapeutics, Inc. (VYGR).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| April 1, 2026 | Shiferman Gregory L. | SVP and General Counsel | A | Common Stock | 50000 | $0.00 | 50,000.0000 | 58,691,136 | 9999.99% | 0.09% |
| April 2, 2026 | Sandrock Alfred | President and CEO | S | Common Stock | 11511 | $3.87 | 472,549.0000 | 58,691,136 | 2.38% | 0.02% |
| Feb. 24, 2026 | Jorgensen Nathan D. | Chief Financial Officer | S | Common Stock | 4668 | $3.77 | 151,416.0000 | 58,803,015 | 2.99% | 0.01% |
| Feb. 24, 2026 | Carter Todd Alfred | Chief Scientific Officer | S | Common Stock | 4174 | $3.76 | 145,718.0000 | 58,803,015 | 2.78% | 0.01% |
| Feb. 24, 2026 | Swartz Robin | COO & CBO | S | Common Stock | 6458 | $3.77 | 199,738.0000 | 58,803,015 | 3.13% | 0.01% |
| Feb. 24, 2026 | Sandrock Alfred | President and CEO | S | Common Stock | 14197 | $3.79 | 484,060.0000 | 58,803,015 | 2.85% | 0.02% |
| Feb. 18, 2026 | Swartz Robin | COO & CBO | S | Common Stock | 3882 | $3.44 | 206,196.0000 | 58,803,015 | 1.85% | 0.01% |
| Feb. 18, 2026 | Carter Todd Alfred | Chief Scientific Officer | S | Common Stock | 3301 | $3.44 | 149,892.0000 | 58,803,015 | 2.15% | 0.01% |
| Feb. 18, 2026 | Sandrock Alfred | President and CEO | S | Common Stock | 11732 | $3.41 | 498,257.0000 | 58,803,015 | 2.30% | 0.02% |
| Feb. 10, 2026 | Carter Todd Alfred | Chief Scientific Officer | S | Common Stock | 3525 | $3.85 | 153,193.0000 | 58,803,015 | 2.25% | 0.01% |
| Feb. 10, 2026 | Sandrock Alfred | President and CEO | S | Common Stock | 12192 | $3.78 | 509,989.0000 | 58,803,015 | 2.33% | 0.02% |
| Feb. 10, 2026 | Swartz Robin | COO & CBO | S | Common Stock | 4569 | $3.85 | 210,078.0000 | 58,803,015 | 2.13% | 0.01% |
| Feb. 6, 2026 | Ferguson Toby | Chief Medical Officer | A | Common Stock | 45000 | $0.00 | 183,914.0000 | 58,803,015 | 32.39% | 0.08% |
| Feb. 6, 2026 | Ferguson Toby | Chief Medical Officer | A | Stock Option (Right to Buy) | 210000 | $0.00 | 210,000.0000 | 58,803,015 | 9999.99% | 0.36% |
| Feb. 6, 2026 | Swartz Robin | COO & CBO | A | Common Stock | 45000 | $0.00 | 214,647.0000 | 58,803,015 | 26.53% | 0.08% |
| Feb. 6, 2026 | Swartz Robin | COO & CBO | A | Stock Option (Right to Buy) | 210000 | $0.00 | 210,000.0000 | 58,803,015 | 9999.99% | 0.36% |
| Feb. 6, 2026 | Sandrock Alfred | President and CEO | A | Common Stock | 86250 | $0.00 | 522,181.0000 | 58,803,015 | 19.79% | 0.15% |
| Feb. 6, 2026 | Sandrock Alfred | President and CEO | A | Stock Option (Right to Buy) | 402500 | $0.00 | 402,500.0000 | 58,803,015 | 9999.99% | 0.68% |
| Feb. 6, 2026 | Jorgensen Nathan D. | Chief Financial Officer | A | Common Stock | 32250 | $0.00 | 156,084.0000 | 58,803,015 | 26.04% | 0.05% |
| Feb. 6, 2026 | Jorgensen Nathan D. | Chief Financial Officer | A | Stock Option (Right to Buy) | 150500 | $0.00 | 150,500.0000 | 58,803,015 | 9999.99% | 0.26% |
| Feb. 6, 2026 | Carter Todd Alfred | Chief Scientific Officer | A | Common Stock | 33000 | $0.00 | 156,718.0000 | 58,803,015 | 26.67% | 0.06% |
| Feb. 6, 2026 | Carter Todd Alfred | Chief Scientific Officer | A | Stock Option (Right to Buy) | 154000 | $0.00 | 154,000.0000 | 58,803,015 | 9999.99% | 0.26% |
| Jan. 6, 2026 | Shiferman Gregory L. | SVP and General Counsel | A | Stock Option (Right to Buy) | 100000 | $0.00 | 100,000.0000 | 58,803,015 | 9999.99% | 0.17% |
| Oct. 3, 2025 | Jorgensen Nathan D. | Chief Financial Officer | S | Common Stock | 7666 | $4.78 | 123,834.0000 | 58,803,015 | 5.83% | 0.01% |
| Aug. 18, 2025 | Ferguson Toby | Chief Medical Officer | S | Common Stock | 19000 | $3.73 | 138,914.0000 | 58,666,460 | 12.03% | 0.03% |
| June 3, 2025 | PIERCE GLENN | Director | A | Stock Option (Right to Buy) | 24000 | $0.00 | 24,000.0000 | 58,349,769 | 9999.99% | 0.04% |
| June 3, 2025 | Onyia Jude | Director | A | Stock Option (Right to Buy) | 24000 | $0.00 | 24,000.0000 | 58,349,769 | 9999.99% | 0.04% |
| June 3, 2025 | MACKEY CATHERINE J | Director | A | Stock Option (Right to Buy) | 24000 | $0.00 | 24,000.0000 | 58,349,769 | 9999.99% | 0.04% |
| June 3, 2025 | Hyman Steven | Director | A | Stock Option (Right to Buy) | 24000 | $0.00 | 24,000.0000 | 58,349,769 | 9999.99% | 0.04% |
| June 3, 2025 | Higgins Michael J | Director | A | Stock Option (Right to Buy) | 24000 | $0.00 | 24,000.0000 | 58,349,769 | 9999.99% | 0.04% |
| June 3, 2025 | Colon Grace | Director | A | Stock Option (Right to Buy) | 24000 | $0.00 | 24,000.0000 | 58,349,769 | 9999.99% | 0.04% |
| June 3, 2025 | Vitale Nancy | Director | A | Stock Option (Right to Buy) | 24000 | $0.00 | 24,000.0000 | 58,349,769 | 9999.99% | 0.04% |
| June 3, 2025 | SCANGOS GEORGE A | Director | A | Stock Option (Right to Buy) | 24000 | $0.00 | 24,000.0000 | 58,349,769 | 9999.99% | 0.04% |
| June 3, 2025 | GERAGHTY JAMES A | Director | A | Stock Option (Right to Buy) | 24000 | $0.00 | 24,000.0000 | 58,349,769 | 9999.99% | 0.04% |
| April 2, 2025 | Ferguson Toby | Chief Medical Officer | S | Common Stock | 10086 | $3.43 | 157,914.0000 | 58,349,769 | 6.00% | 0.02% |
| April 2, 2025 | Sandrock Alfred | President and CEO | S | Common Stock | 10885 | $3.43 | 430,931.0000 | 58,349,769 | 2.46% | 0.02% |
| Feb. 21, 2025 | Swartz Robin | COO & CBO | A | Common Stock | 71250 | $0.00 | 169,647.0000 | 57,667,543 | 72.41% | 0.12% |
| Feb. 20, 2025 | Carter Todd Alfred | Chief Scientific Officer | S | Common Stock | 3305 | $4.26 | 77,718.0000 | 57,667,543 | 4.08% | 0.01% |
| Feb. 21, 2025 | Carter Todd Alfred | Chief Scientific Officer | A | Common Stock | 46000 | $0.00 | 123,718.0000 | 57,667,543 | 59.19% | 0.08% |
| Feb. 21, 2025 | Carter Todd Alfred | Chief Scientific Officer | A | Stock Option (Right to Buy) | 92000 | $0.00 | 92,000.0000 | 57,667,543 | 9999.99% | 0.16% |
| Feb. 20, 2025 | Sandrock Alfred | President and CEO | S | Common Stock | 11702 | $4.24 | 296,816.0000 | 57,667,543 | 3.79% | 0.02% |
| Feb. 21, 2025 | Sandrock Alfred | President and CEO | A | Common Stock | 145000 | $0.00 | 441,816.0000 | 57,667,543 | 48.85% | 0.25% |
| Feb. 21, 2025 | Sandrock Alfred | President and CEO | A | Stock Option (Right to Buy) | 290000 | $0.00 | 290,000.0000 | 57,667,543 | 9999.99% | 0.50% |
| Feb. 20, 2025 | Swartz Robin | COO & CBO | S | Common Stock | 3894 | $4.25 | 98,397.0000 | 57,667,543 | 3.81% | 0.01% |
| Feb. 21, 2025 | Swartz Robin | COO & CBO | A | Stock Option (Right to Buy) | 142500 | $0.00 | 142,500.0000 | 57,667,543 | 9999.99% | 0.25% |
| Feb. 21, 2025 | Fahey Sandell Jacquelyn | Chief Legal Officer | A | Common Stock | 41500 | $0.00 | 123,143.0000 | 57,667,543 | 50.83% | 0.07% |
| Feb. 21, 2025 | Fahey Sandell Jacquelyn | Chief Legal Officer | A | Stock Option (Right to Buy) | 83000 | $0.00 | 83,000.0000 | 57,667,543 | 9999.99% | 0.14% |
| Feb. 21, 2025 | Ferguson Toby | Chief Medical Officer | A | Common Stock | 63000 | $0.00 | 168,000.0000 | 57,667,543 | 60.00% | 0.11% |
| Feb. 21, 2025 | Ferguson Toby | Chief Medical Officer | A | Stock Option (Right to Buy) | 126000 | $0.00 | 126,000.0000 | 57,667,543 | 9999.99% | 0.22% |
| Feb. 21, 2025 | Jorgensen Nathan D. | Chief Financial Officer | A | Common Stock | 51500 | $0.00 | 131,500.0000 | 57,667,543 | 64.38% | 0.09% |
| Feb. 21, 2025 | Jorgensen Nathan D. | Chief Financial Officer | A | Stock Option (Right to Buy) | 103000 | $0.00 | 103,000.0000 | 57,667,543 | 9999.99% | 0.18% |
| Feb. 11, 2025 | Carter Todd Alfred | Chief Scientific Officer | S | Common Stock | 5413 | $4.45 | 81,023.0000 | 57,667,543 | 6.26% | 0.01% |
| Feb. 11, 2025 | Swartz Robin | COO & CBO | S | Common Stock | 6950 | $4.45 | 102,291.0000 | 57,667,543 | 6.36% | 0.01% |
| Feb. 11, 2025 | Fahey Sandell Jacquelyn | Chief Legal Officer | S | Common Stock | 4358 | $4.45 | 81,643.0000 | 57,667,543 | 5.07% | 0.01% |
| Feb. 11, 2025 | Sandrock Alfred | President & CEO | S | Common Stock | 16644 | $4.45 | 308,518.0000 | 57,667,543 | 5.12% | 0.03% |
| Jan. 14, 2025 | Carter Todd Alfred | Chief Scientific Officer | S | Common Stock | 1191 | $5.13 | 86,436.0000 | 57,667,543 | 1.36% | 0.00% |
| Jan. 14, 2025 | Swartz Robin | COO & CBO | S | Common Stock | 3087 | $5.09 | 109,241.0000 | 57,667,543 | 2.75% | 0.01% |
| Dec. 23, 2024 | Swartz Robin | COO&CBO | S | Common Stock | 6500 | $5.65 | 112,328.0000 | 57,851,110 | 5.47% | 0.01% |
| Oct. 2, 2024 | Fahey Sandell Jacquelyn | Chief Legal Officer | S | Common Stock | 5999 | $5.82 | 86,001.0000 | 57,851,110 | 6.52% | 0.01% |
| Oct. 1, 2024 | Jorgensen Nathan D. | Chief Financial Officer | A | Common Stock | 80000 | $0.00 | 80,000.0000 | 57,851,110 | 9999.99% | 0.14% |
| July 8, 2024 | Jorgensen Nathan D. | Chief Financial Officer | A | Stock Option (Right to Buy) | 200000 | $0.00 | 200,000.0000 | 57,721,934 | 9999.99% | 0.35% |
| June 5, 2024 | PIERCE GLENN | Director | A | Stock Option (Right to Buy) | 24000 | $0.00 | 24,000.0000 | 57,117,046 | 9999.99% | 0.04% |
| June 5, 2024 | MACKEY CATHERINE J | Director | A | Stock Option (Right to Buy) | 24000 | $0.00 | 24,000.0000 | 57,117,046 | 9999.99% | 0.04% |
| June 5, 2024 | Hyman Steven | Director | A | Stock Option (Right to Buy) | 24000 | $0.00 | 24,000.0000 | 57,117,046 | 9999.99% | 0.04% |
| June 5, 2024 | Higgins Michael J | Director | A | Stock Option (Right to Buy) | 24000 | $0.00 | 24,000.0000 | 57,117,046 | 9999.99% | 0.04% |
| June 5, 2024 | GERAGHTY JAMES A | Director | A | Stock Option (Right to Buy) | 24000 | $0.00 | 24,000.0000 | 57,117,046 | 9999.99% | 0.04% |
| June 5, 2024 | Colon Grace | Director | A | Stock Option (Right to Buy) | 24000 | $0.00 | 24,000.0000 | 57,117,046 | 9999.99% | 0.04% |
| June 5, 2024 | Vitale Nancy | Director | A | Stock Option (Right to Buy) | 24000 | $0.00 | 24,000.0000 | 57,117,046 | 9999.99% | 0.04% |
| June 5, 2024 | SCANGOS GEORGE A | Director | A | Stock Option (Right to Buy) | 24000 | $0.00 | 24,000.0000 | 57,117,046 | 9999.99% | 0.04% |
| June 5, 2024 | Onyia Jude | Director | A | Stock Option (Right to Buy) | 24000 | $0.00 | 24,000.0000 | 57,117,046 | 9999.99% | 0.04% |
| April 1, 2024 | Ferguson Toby | Chief Medical Officer | A | Common Stock | 105000 | $0.00 | 105,000.0000 | 57,117,046 | 9999.99% | 0.18% |
| April 2, 2024 | Sandrock Alfred | President and CEO | S | Common Stock | 12115 | $9.86 | 322,839.0000 | 57,117,046 | 3.62% | 0.02% |
| April 2, 2024 | Swartz Robin | Chief Operating Officer | S | Common Stock | 1357 | $9.88 | 117,004.0000 | 57,117,046 | 1.15% | 0.00% |
| March 25, 2024 | Ferguson Toby | Chief Medical Officer | A | Stock Option (Right to Buy) | 210000 | $0.00 | 210,000.0000 | 44,569,334 | 9999.99% | 0.47% |
| Feb. 20, 2024 | Carter Todd Alfred | Chief Scientific Officer | S | Common Stock | 602 | $7.68 | 90,992.0000 | 44,569,334 | 0.66% | 0.00% |
| Feb. 21, 2024 | Sandrock Alfred | President and CEO | S | Common Stock | 13033 | $7.46 | 334,954.0000 | 44,569,334 | 3.75% | 0.03% |
| Feb. 21, 2024 | PFREUNDSCHUH PETER P. | Chief Financial Officer | S | Common Stock | 3764 | $7.46 | 175,669.0000 | 44,569,334 | 2.10% | 0.01% |
| Feb. 21, 2024 | Swartz Robin | Chief Operating Officer | S | Common Stock | 3966 | $7.45 | 118,361.0000 | 44,569,334 | 3.24% | 0.01% |
| Feb. 21, 2024 | Carter Todd Alfred | Chief Scientific Officer | S | Common Stock | 3365 | $7.47 | 87,627.0000 | 44,569,334 | 3.70% | 0.01% |
| Feb. 9, 2024 | PFREUNDSCHUH PETER P. | Chief Financial Officer | A | Common Stock | 30000 | $0.00 | 179,433.0000 | 44,569,334 | 20.08% | 0.07% |
| Feb. 9, 2024 | Fahey Sandell Jacquelyn | Chief Legal Officer | A | Common Stock | 31000 | $0.00 | 92,000.0000 | 44,569,334 | 50.82% | 0.07% |
| Feb. 9, 2024 | Fahey Sandell Jacquelyn | Chief Legal Officer | A | Stock Option (Right to Buy) | 62000 | $0.00 | 62,000.0000 | 44,569,334 | 9999.99% | 0.14% |
| Feb. 9, 2024 | Carter Todd Alfred | Chief Scientific Officer | A | Common Stock | 38500 | $0.00 | 91,594.0000 | 44,569,334 | 72.51% | 0.09% |
| Feb. 9, 2024 | Carter Todd Alfred | Chief Scientific Officer | A | Stock Option (Right to Buy) | 77000 | $0.00 | 77,000.0000 | 44,569,334 | 9999.99% | 0.17% |
| Feb. 9, 2024 | Swartz Robin | Chief Operating Officer | A | Common Stock | 50000 | $0.00 | 122,327.0000 | 44,569,334 | 69.13% | 0.11% |
| Feb. 9, 2024 | Swartz Robin | Chief Operating Officer | A | Stock Option (Right to Buy) | 100000 | $0.00 | 100,000.0000 | 44,569,334 | 9999.99% | 0.22% |
| Feb. 9, 2024 | Sandrock Alfred | President and CEO | A | Common Stock | 130000 | $0.00 | 347,987.0000 | 44,569,334 | 59.64% | 0.29% |
| Feb. 9, 2024 | Sandrock Alfred | President and CEO | A | Stock Option (Right to Buy) | 260000 | $0.00 | 260,000.0000 | 44,569,334 | 9999.99% | 0.58% |
| Feb. 9, 2024 | PFREUNDSCHUH PETER P. | Chief Financial Officer | A | Stock Option (Right to Buy) | 60000 | $0.00 | 60,000.0000 | 44,569,334 | 9999.99% | 0.13% |
| Jan. 17, 2024 | Swartz Robin | Chief Operating Officer | S | Common Stock | 2543 | $7.15 | 72,327.0000 | 44,569,334 | 3.40% | 0.01% |
| Jan. 17, 2024 | Carter Todd Alfred | Chief Scientific Officer | S | Common Stock | 1266 | $7.18 | 53,094.0000 | 44,569,334 | 2.33% | 0.00% |
| Oct. 3, 2023 | PFREUNDSCHUH PETER P. | Chief Financial Officer | S | Common Stock | 13567 | $6.99 | 149,433.0000 | 43,864,838 | 8.32% | 0.03% |
| Oct. 1, 2023 | Fahey Sandell Jacquelyn | Chief Legal Officer | A | Common Stock | 61000 | $0.00 | 61,000.0000 | 43,864,838 | 9999.99% | 0.14% |
| Sept. 15, 2023 | Carter Todd Alfred | Chief Scientific Officer | M | Common Stock | 5000 | $2.85 | 64,860.0000 | 43,520,137 | 8.35% | 0.01% |
| Sept. 15, 2023 | Carter Todd Alfred | Chief Scientific Officer | M | Stock Option (Right to Buy) | 5000 | $0.00 | 40,000.0000 | 43,520,137 | 11.11% | 0.01% |
| Sept. 15, 2023 | Carter Todd Alfred | Chief Scientific Officer | S | Common Stock | 10500 | $8.16 | 54,360.0000 | 43,520,137 | 16.19% | 0.02% |
| July 10, 2023 | Fahey Sandell Jacquelyn | Chief Legal Officer | A | Stock Option (Right to Buy) | 122000 | $0.00 | 122,000.0000 | 43,520,137 | 9999.99% | 0.28% |
| July 6, 2023 | Carter Todd Alfred | Chief Scientific Officer | S | Common Stock | 5500 | $10.80 | 59,860.0000 | 43,520,137 | 8.41% | 0.01% |
| June 30, 2023 | Carter Todd Alfred | Chief Scientific Officer | M | Stock Option (Right to Buy) | 5000 | $0.00 | 45,000.0000 | 42,161,326 | 10.00% | 0.01% |
| June 30, 2023 | Carter Todd Alfred | Chief Scientific Officer | S | Common Stock | 5000 | $11.41 | 65,360.0000 | 42,161,326 | 7.11% | 0.01% |
| June 30, 2023 | Carter Todd Alfred | Chief Scientific Officer | M | Common Stock | 5000 | $2.85 | 70,360.0000 | 42,161,326 | 7.65% | 0.01% |
| June 6, 2023 | MACKEY CATHERINE J | Director | A | Stock Option (Right to Buy) | 22000 | $0.00 | 22,000.0000 | 42,161,326 | 9999.99% | 0.05% |
| June 6, 2023 | Vitale Nancy | Director | A | Stock Option (Right to Buy) | 22000 | $0.00 | 22,000.0000 | 42,161,326 | 9999.99% | 0.05% |
| June 6, 2023 | Onyia Jude | Director | A | Stock Option (Right to Buy) | 22000 | $0.00 | 22,000.0000 | 42,161,326 | 9999.99% | 0.05% |
| June 6, 2023 | Higgins Michael J | Director | A | Stock Option (Right to Buy) | 22000 | $0.00 | 22,000.0000 | 42,161,326 | 9999.99% | 0.05% |
| June 6, 2023 | Colon Grace | Director | A | Stock Option (Right to Buy) | 22000 | $0.00 | 22,000.0000 | 42,161,326 | 9999.99% | 0.05% |
| June 6, 2023 | GERAGHTY JAMES A | Director | A | Stock Option (Right to Buy) | 22000 | $0.00 | 22,000.0000 | 42,161,326 | 9999.99% | 0.05% |
| June 6, 2023 | SCANGOS GEORGE A | Director | A | Stock Option (Right to Buy) | 22000 | $0.00 | 22,000.0000 | 42,161,326 | 9999.99% | 0.05% |
| June 6, 2023 | Hyman Steven | Director | A | Stock Option (Right to Buy) | 22000 | $0.00 | 22,000.0000 | 42,161,326 | 9999.99% | 0.05% |
| June 6, 2023 | PIERCE GLENN | Director | A | Stock Option (Right to Buy) | 22000 | $0.00 | 22,000.0000 | 42,161,326 | 9999.99% | 0.05% |
| May 9, 2023 | SCANGOS GEORGE A | Director | A | Stock Option (Right to Buy) | 44000 | $0.00 | 44,000.0000 | 42,161,326 | 9999.99% | 0.10% |
| April 3, 2023 | Sandrock Alfred | President and CEO | S | Common Stock | 7437 | $7.83 | 214,618.0000 | 42,161,326 | 3.35% | 0.02% |
| April 3, 2023 | Swartz Robin | Chief Operating Officer | S | Common Stock | 1259 | $7.83 | 71,617.0000 | 42,161,326 | 1.73% | 0.00% |
| March 20, 2023 | Swartz Robin | Chief Operating Officer | S | Common Stock | 3654 | $7.76 | 72,876.0000 | 38,356,810 | 4.77% | 0.01% |
| March 20, 2023 | Carter Todd Alfred | Chief Scientific Officer | S | Common Stock | 2193 | $7.76 | 65,360.0000 | 38,356,810 | 3.25% | 0.01% |
| March 20, 2023 | Hesslein Robert W. | Senior VP & General Counsel | S | Common Stock | 4410 | $7.76 | 102,200.0000 | 38,356,810 | 4.14% | 0.01% |
| March 15, 2023 | Swartz Robin | Chief Operating Officer | S | Common Stock | 15373 | $8.20 | 76,530.0000 | 38,356,810 | 16.73% | 0.04% |
| Feb. 23, 2023 | Onyia Jude | Director | A | Stock Option (Right to Buy) | 44000 | $0.00 | 44,000.0000 | 38,356,810 | 9999.99% | 0.11% |
| Feb. 23, 2023 | NEUROCRINE BIOSCIENCES INC | TenPercentOwner | P | Common Stock | 4395588 | $8.88 | 8,575,316.0000 | 38,356,810 | 105.16% | 11.46% |
| Feb. 17, 2023 | Swartz Robin | Chief Operating Officer | A | Stock Option (Right to Buy) | 80000 | $0.00 | 80,000.0000 | 38,356,810 | 9999.99% | 0.21% |
| Feb. 17, 2023 | Hesslein Robert W. | Senior VP & General Counsel | S | Common Stock | 3297 | $7.45 | 106,610.0000 | 38,356,810 | 3.00% | 0.01% |
| Feb. 17, 2023 | Carter Todd Alfred | Chief Scientific Officer | A | Common Stock | 34000 | $0.00 | 68,291.0000 | 38,356,810 | 99.15% | 0.09% |
| Feb. 17, 2023 | Carter Todd Alfred | Chief Scientific Officer | S | Common Stock | 738 | $7.45 | 67,553.0000 | 38,356,810 | 1.08% | 0.00% |
| Feb. 17, 2023 | Carter Todd Alfred | Chief Scientific Officer | A | Stock Option (Right to Buy) | 68000 | $0.00 | 68,000.0000 | 38,356,810 | 9999.99% | 0.18% |
| Feb. 17, 2023 | PFREUNDSCHUH PETER P. | Chief Financial Officer | A | Common Stock | 38000 | $0.00 | 163,000.0000 | 38,356,810 | 30.40% | 0.10% |
| Feb. 17, 2023 | PFREUNDSCHUH PETER P. | Chief Financial Officer | A | Stock Option (Right to Buy) | 76000 | $0.00 | 76,000.0000 | 38,356,810 | 9999.99% | 0.20% |
| Feb. 17, 2023 | Swartz Robin | Chief Operating Officer | A | Common Stock | 40000 | $0.00 | 91,903.0000 | 38,356,810 | 77.07% | 0.10% |
| Feb. 17, 2023 | Sandrock Alfred | President and CEO | A | Common Stock | 120000 | $0.00 | 222,055.0000 | 38,356,810 | 117.58% | 0.31% |
| Feb. 17, 2023 | Sandrock Alfred | President and CEO | A | Stock Option (Right to Buy) | 240000 | $0.00 | 240,000.0000 | 38,356,810 | 9999.99% | 0.63% |
| Feb. 13, 2023 | Carter Todd Alfred | Chief Scientific Officer | S | Common Stock | 797 | $7.67 | 34,291.0000 | 38,356,810 | 2.27% | 0.00% |
| Feb. 13, 2023 | Hesslein Robert W. | Senior VP & General Counsel | S | Common Stock | 2868 | $7.67 | 109,907.0000 | 38,356,810 | 2.54% | 0.01% |
| Feb. 2, 2023 | Third Rock Ventures III, L.P. | TenPercentOwner | J | Common Stock | 1500000 | $0.00 | 3,271,556.0000 | 38,356,810 | 31.44% | 3.91% |
| Feb. 1, 2023 | Third Rock Ventures III, L.P. | TenPercentOwner | S | Common Stock | 128642 | $9.32 | 4,721,992.0000 | 38,356,810 | 2.65% | 0.34% |
| Jan. 30, 2023 | Third Rock Ventures III, L.P. | TenPercentOwner | S | Common Stock | 75000 | $9.03 | 5,035,634.0000 | 38,356,810 | 1.47% | 0.20% |
| Jan. 31, 2023 | Third Rock Ventures III, L.P. | TenPercentOwner | S | Common Stock | 185000 | $9.25 | 4,850,634.0000 | 38,356,810 | 3.67% | 0.48% |
| Jan. 27, 2023 | Third Rock Ventures III, L.P. | TenPercentOwner | S | Common Stock | 50000 | $9.02 | 5,110,634.0000 | 38,356,810 | 0.97% | 0.13% |
| Jan. 25, 2023 | Third Rock Ventures III, L.P. | TenPercentOwner | S | Common Stock | 50000 | $9.22 | 5,160,634.0000 | 38,356,810 | 0.96% | 0.13% |
| Jan. 24, 2023 | Third Rock Ventures III, L.P. | TenPercentOwner | S | Common Stock | 100000 | $9.27 | 5,210,634.0000 | 38,356,810 | 1.88% | 0.26% |
| Jan. 20, 2023 | Third Rock Ventures III, L.P. | TenPercentOwner | S | Common Stock | 100000 | $9.15 | 5,365,634.0000 | 38,356,810 | 1.83% | 0.26% |
| Jan. 23, 2023 | Third Rock Ventures III, L.P. | TenPercentOwner | S | Common Stock | 55000 | $9.06 | 5,310,634.0000 | 38,356,810 | 1.03% | 0.14% |
| Jan. 17, 2023 | Hesslein Robert W. | Senior VP & General Counsel | S | Common Stock | 1396 | $9.57 | 113,567.0000 | 38,356,810 | 1.21% | 0.00% |
| Jan. 17, 2023 | Swartz Robin | Chief Operating Officer | S | Common Stock | 792 | $10.34 | 51,903.0000 | 38,356,810 | 1.50% | 0.00% |
| Jan. 17, 2023 | Swartz Robin | Chief Operating Officer | S | Common Stock | 1396 | $9.57 | 52,695.0000 | 38,356,810 | 2.58% | 0.00% |
| Jan. 17, 2023 | Carter Todd Alfred | Chief Scientific Officer | S | Common Stock | 400 | $10.34 | 35,088.0000 | 38,356,810 | 1.13% | 0.00% |
| Jan. 17, 2023 | Carter Todd Alfred | Chief Scientific Officer | S | Common Stock | 706 | $9.57 | 35,488.0000 | 38,356,810 | 1.95% | 0.00% |
| Jan. 17, 2023 | Hesslein Robert W. | Senior VP & General Counsel | S | Common Stock | 792 | $10.34 | 112,775.0000 | 38,356,810 | 0.70% | 0.00% |
| Jan. 9, 2023 | EcoR1 Capital, LLC | TenPercentOwner | S | Common Stock | 456000 | $7.67 | 4,297,907.0000 | 38,356,810 | 9.59% | 1.19% |
| Jan. 10, 2023 | EcoR1 Capital, LLC | TenPercentOwner | S | Common Stock | 336400 | $8.05 | 3,961,507.0000 | 38,356,810 | 7.83% | 0.88% |
| Jan. 11, 2023 | EcoR1 Capital, LLC | TenPercentOwner | S | Common Stock | 110000 | $8.50 | 3,851,507.0000 | 38,356,810 | 2.78% | 0.29% |
| Dec. 31, 2022 | Carter Todd Alfred | Chief Scientific Officer | A | Common Stock | 388 | $5.17 | 36,582.0000 | 39,570,394 | 1.07% | 0.00% |
| Jan. 6, 2023 | Carter Todd Alfred | Chief Scientific Officer | S | Common Stock | 388 | $6.41 | 36,194.0000 | 38,356,810 | 1.06% | 0.00% |
| Jan. 1, 2023 | Colon Grace | Director | A | Stock Option (Right to Buy) | 44000 | $0.00 | 44,000.0000 | 38,356,810 | 9999.99% | 0.11% |